To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Shanghai Henlius Biotech
- Study ID
- NCT05468489
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Extensive Stage Small Cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Serplulimab + chemotherapy (carboplatin-etoposide) — DRUGDrug: Serplulimab is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc. Drug: carboplatin and etoposide chemotherapeutics
- Atezolizumab + chemotherapy (carboplatin-etoposide) — DRUGDrug: Atezolizumab is a monoclonal antibody targeting PD-L1,developed by Roche Pharma AG. Drug: carboplatin and etoposide chemotherapeutics
Study Details
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Key Dates
- Start date
- Nov 18, 2022
- Status verified
- Oct 2025
- Primary completion
- Feb 28, 2026
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Serplulimab + chemotherapySerplulimab + chemotherapy (carboplatin-etoposide)
- Active Comparator: Atezolizumab + chemotherapyAtezolizumab + chemotherapy (carboplatin-etoposide)
Primary Outcome Measure
OS [ Time Frame: A period from randomization through death regardless of causality (approximately up to 24 months). ]
Locations (67)
Related coverage on Hipa.ai
- Atezolizumab Trial for ES-SCLC Reaches Primary CompletionAtezolizumab · Feb 28, 2026 · ClinicalTrials.gov
Find similar trials in Birmingham, AL
Related Studies
- Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerPHASE2 · Recruiting · Muhammad Furqan · Chicago, Illinois
- MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerPHASE2 · Recruiting · Hirva Mamdani · Indianapolis, Indiana
- Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)PHASE1 · Recruiting · Amgen · Los Angeles, California
- A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)PHASE1 · Recruiting · Amgen · Gilbert, Arizona